Use access key #2 to skip to page content.

JimVanMeerten (56.04)

Techne -- TECH -- Biomedical buy



May 02, 2011 – Comments (0) | RELATED TICKERS: TECH

Most of my picks are what some people call momentum investing.  I do not look for patterns but I do use Barchart to find stocks with upward momentum that deserve to be recognized for their increases in sales and earnings.  Techne (TECH) is just such a stock.

Techne Corporation (TECH) is a holding company which has two wholly-owned operating subsidiaries: Research and Diagnostic Systems, Inc. and R&D Systems Europe Ltd. Research and Diagnostic Systems, Inc. is a specialty manufacturer of biological products. R&D Europe distributes Research and Diagnostic Systems' biotechnology products in Europe. Its two major operating segments are hematology controls, which are used in hospital and clinical laboratories to check the accuracy of blood analysis instruments, and biotechnology products including purified proteins and antibodies.

Technical Factors to consider:

1 - 100% Barchart technical buy signal

2 - Trend Spotter buy signal

3 - 10 new highs and up 7.89% in the last month

4 - Relative Strength Index 78.77 and rising

5 - Trades around 78.37 with a 50 day moving average of 72.82

Fundamental Factors:

1 - Wall Street brokerage analysts have issued 5 recommendations on this stock

2 - There are 2 strong buy, 1 buy 2 hold and no negative recommendations released

3 - Sales are expected to increase by 4.40% this year and 7.00% next year

4 - Earning are projected to increase by 5.70% this year, 8.40% next year and 10.33% annually for the next 5 years.

General Investor Sentiment:

1 - As measured on Motley Fool there is a very positive investor sentiment for this stock to beat the market

2 - CAPS members vote 272 to 8 for that to happen

3 - The more experienced All Stars vote 104 to 1 for the same result

This is a stock with positive momentum, Wall Street buy recommendations based on forecasts of increased sales and earnings and has a positive investor following.  It definitely deserves a place on your watch lists.

Jim Van Meerten is an analyst for  Marketocracy Capital Management.  He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on  in his daily blog -- Barchart Portfolio Blogs.

0 Comments – Post Your Own

Featured Broker Partners